Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy

Atherosclerosis is associated with various pathological manifestations, such as ischemic heart disease, ischemic stroke, and peripheral arterial disease, and remains a leading cause of public health concern. Atherosclerosis is an inflammatory disease characterized by endothelial dysfunction; vascula...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: BingYu Wang, Jun Qiu, JiangFang Lian, Xi Yang, JianQing Zhou
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/e8a9bb3ab4314e5abc746cabc4336c9e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e8a9bb3ab4314e5abc746cabc4336c9e
record_format dspace
spelling oai:doaj.org-article:e8a9bb3ab4314e5abc746cabc4336c9e2021-11-30T14:29:17ZGut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy2297-055X10.3389/fcvm.2021.723886https://doaj.org/article/e8a9bb3ab4314e5abc746cabc4336c9e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.723886/fullhttps://doaj.org/toc/2297-055XAtherosclerosis is associated with various pathological manifestations, such as ischemic heart disease, ischemic stroke, and peripheral arterial disease, and remains a leading cause of public health concern. Atherosclerosis is an inflammatory disease characterized by endothelial dysfunction; vascular inflammation; and the deposition of lipids, cholesterol, calcium, and cellular debris within the vessel wall intima. In-depth studies of gut flora in recent years have shown that bacterial translocation and the existence of bacterial active products in blood circulation can affect the inflammatory state of the whole blood vessel. The gut flora is considered to be a large “secretory organ,” which produces trimethylamine-N-oxide (TMAO), short-chain fatty acids and secondary bile acids by breaking down the ingested food. Studies have shown that TMAO is an independent risk factor for the occurrence of malignant adverse cardiovascular events, but whether it is harmful or beneficial to patients with cardiovascular diseases with mild or no clinical manifestations remains controversial. We review the relationship between TMAO and its precursor (L-carnitine) and coronary atherosclerosis and summarize the potential molecular mechanism and therapeutic measures of TMAO on coronary atherosclerosis.BingYu WangJun QiuJiangFang LianJiangFang LianXi YangJianQing ZhouJianQing ZhouFrontiers Media S.A.articleTMAOL-carnitineatherosclerosisendoplasmic reticulum stressvascular calcificationDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution DOAJ
collection DOAJ
language EN
topic TMAO
L-carnitine
atherosclerosis
endoplasmic reticulum stress
vascular calcification
Diseases of the circulatory (Cardiovascular) system
RC666-701
spellingShingle TMAO
L-carnitine
atherosclerosis
endoplasmic reticulum stress
vascular calcification
Diseases of the circulatory (Cardiovascular) system
RC666-701
BingYu Wang
Jun Qiu
JiangFang Lian
JiangFang Lian
Xi Yang
JianQing Zhou
JianQing Zhou
Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy
description Atherosclerosis is associated with various pathological manifestations, such as ischemic heart disease, ischemic stroke, and peripheral arterial disease, and remains a leading cause of public health concern. Atherosclerosis is an inflammatory disease characterized by endothelial dysfunction; vascular inflammation; and the deposition of lipids, cholesterol, calcium, and cellular debris within the vessel wall intima. In-depth studies of gut flora in recent years have shown that bacterial translocation and the existence of bacterial active products in blood circulation can affect the inflammatory state of the whole blood vessel. The gut flora is considered to be a large “secretory organ,” which produces trimethylamine-N-oxide (TMAO), short-chain fatty acids and secondary bile acids by breaking down the ingested food. Studies have shown that TMAO is an independent risk factor for the occurrence of malignant adverse cardiovascular events, but whether it is harmful or beneficial to patients with cardiovascular diseases with mild or no clinical manifestations remains controversial. We review the relationship between TMAO and its precursor (L-carnitine) and coronary atherosclerosis and summarize the potential molecular mechanism and therapeutic measures of TMAO on coronary atherosclerosis.
format article
author BingYu Wang
Jun Qiu
JiangFang Lian
JiangFang Lian
Xi Yang
JianQing Zhou
JianQing Zhou
author_facet BingYu Wang
Jun Qiu
JiangFang Lian
JiangFang Lian
Xi Yang
JianQing Zhou
JianQing Zhou
author_sort BingYu Wang
title Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy
title_short Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy
title_full Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy
title_fullStr Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy
title_full_unstemmed Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy
title_sort gut metabolite trimethylamine-n-oxide in atherosclerosis: from mechanism to therapy
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/e8a9bb3ab4314e5abc746cabc4336c9e
work_keys_str_mv AT bingyuwang gutmetabolitetrimethylaminenoxideinatherosclerosisfrommechanismtotherapy
AT junqiu gutmetabolitetrimethylaminenoxideinatherosclerosisfrommechanismtotherapy
AT jiangfanglian gutmetabolitetrimethylaminenoxideinatherosclerosisfrommechanismtotherapy
AT jiangfanglian gutmetabolitetrimethylaminenoxideinatherosclerosisfrommechanismtotherapy
AT xiyang gutmetabolitetrimethylaminenoxideinatherosclerosisfrommechanismtotherapy
AT jianqingzhou gutmetabolitetrimethylaminenoxideinatherosclerosisfrommechanismtotherapy
AT jianqingzhou gutmetabolitetrimethylaminenoxideinatherosclerosisfrommechanismtotherapy
_version_ 1718406536809676800